|Table of Contents|

Clinical efficacy and influencing factors of autologous hematopoietic stem cell transplantation in the treatment of highly aggressive lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3086-3091
Research Field:
Publishing date:

Info

Title:
Clinical efficacy and influencing factors of autologous hematopoietic stem cell transplantation in the treatment of highly aggressive lymphoma
Author(s):
LIU Donglin1; 2; ZHANG Xudong1; 2; QIAN Siyu1; 2; HOU Huting1; 2; WANG Yanjie1; 2; MA Shanshan1; 2; ZHANG Wenjun2; 3
1.Department of Medical Oncology,the First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450002,China;2.Henan Lymphoma Center,Henan Zhengzhou 450052,China;3.Department of Medical Oncology,the Third Affiliated Hospital of Xinxiang Medical College,Henan Xinxiang 453000,China.
Keywords:
autologous hematopoietic stem cell transplantation; highly aggressive lymphoma; efficacy; influencing factors
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.16.027
Abstract:
Objective:To investigate the clinical efficacy and related factors of autologous hematopoietic stem cell transplantation (Auto-HSCT) in the treatment of highly aggressive lymphoma.Methods:The clinical data of 88 patients with highly aggressive lymphoma from July 2011 to August 2021 in our hospital were retrospectively analyzed.There were 33 patients with BL,13 in the Auto-HSCT group and 20 in the chemotherapy group.There were 53 patients with T-LBL,25 in the Auto-HSCT group and 28 in the chemotherapy group.2 patients with B-LBL 2 in the Auto-HSCT group.Results:The BL Auto-HSCT group had 12 cases of progression-free survival,1 case of relapse,and all patients survived.In the chemotherapy group,15 patients survived progression-free,5 relapsed,16 survived,and 4 died.The PFS rates at 1 and 3 years were 92% and 53% in the Auto-HSCT group and 65% and 10% in the chemotherapy group,with no statistically significant efficacy in the two groups (P=0.167).The OS rates at 1 and 3 years were 100% and 61% in the Auto-HSCT group and 70% and 10% in the chemotherapy group,with no statistically significant efficacy in the two groups (P=0.073).The T-LBL Auto-HSCT group had 13 cases of progression-free survival,12 cases of relapse,and 2 cases of death.In the chemotherapy alone group,there were 3 cases of progression-free survival,25 cases of relapse and 25 deaths.The PFS rates at 1 and 3 years were 80% and 24% in the Auto-HSCT group and 32% and 10% in the chemotherapy group,with statistically significant differences in efficacy between the two groups (P＜0.01).The OS rates at 1 and 3 years were 92% and 36% in the Auto-HSCT group and 39% and 18% in the chemotherapy group,with statistically significant differences in efficacy between the two groups (P＜0.01).Two patients with B-lymphoblastic lymphoma Auto-HSCT,one survived disease free and one died after relapse.Conclusion:Chemotherapy sequential Auto-HSCT significantly improves the prognosis of BL patients and may also be an option for consolidation and salvage therapy for patients with T-lymphoblastic lymphoma.

References:

［1］ CROMBIE J,LACASCE A.The treatment of Burkitt lymphoma in adults ［J］.Blood,2021,137(6):743-750.
［2］ 苏丽萍.淋巴母细胞淋巴瘤生物学特征与治疗进展 ［J］.中国实用内科杂志,2015,35(02):102-106. SU LP.Biological characteristics and treatment progress of lymphoblastic lymphoma［J］.Chinese Journal of Practical Internal Medicine,2015,35(02):102-106.
［3］ SWERDLOW SH,CAMPO E,PILERI SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms ［J］.Blood,2016,127(20):2375-2390.
［4］ BASSAN R,MAINO E,CORTELAZZO S.Lymphoblastic lymphoma:an updated review on biology,diagnosis,and treatment ［J］.Eur J Haematol,2016,96(5):447-460.
［5］ SHI Y,ZHOU S,HE X,et al.Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma:treatment outcome and prognostic factor analysis ［J］.Chin J Cancer Res,2015,27(1):66-73.
［6］ 王普，李彩霞，张莹，等.自体造血干细胞移植治疗T淋巴母细胞淋巴瘤41例临床研究 ［J］.中华血液学杂志,2020,41(3):198-203. WANG P,LI CX,ZHANG Y,et al.Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma［J］.Chinese Journal of Hematology,2020，41(3):198-203.
［7］ COLITA A,COLITA A,BUMBEA H,et al.LEAM vs BEAM vs CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas.retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant,on behalf of the romanian society for bone marrow transplantation ［J］.Front Oncol,2019,9:892.
［8］ XU LP,LU PH,WU DP,et al.Hematopoietic stem cell transplantation activity in China 2019:a report from the Chinese Blood and Marrow Transplantation Registry Group ［J］.Bone Marrow Transplant,2021,56(12):2940-2947.
［9］ LEVINE JE,HARRIS RE,LOBERIZA FR,et al.A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma ［J］.Blood,2003,101(7):2476-2482. WANG P,LI CX,ZHANG Y,et al.Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma［J］.Chinese Journal of Hematology,2020，41(3):198-203.
［10］ LIU Y,RAO J,LI J,et al.Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma:a multiple center prospective study in China ［J］.Haematologica,2021,106(1):163-172.
［11］ 申昱妍，陈书连，杨栋林，等.成人急性淋巴细胞白血病自体和异基因造血干细胞移植疗效对比分析 ［J］.中华血液学杂志,2015,36(03):210-215. SHEN YY,CHEN SL,YANG DL,et al.Comparison of outcomes of adult acute lymphoblastic leukemia patients underwent autologous and allogeneic hematopoietic stem cell transplantation［J］.Chinese Journal of Hematology,2015,36(03):210-215.
［12］ PATEL B,RAI L,BUCK G,et al.Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia:final results of the international trial UKALL XII/ECOG2993 ［J］.Br J Haematol,2010,148(1):80-89.
［13］ GIEBEL S,STELLA-HOLOWIECKA B,KRAWCZYK-KULIS M,et al.Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL ［J］.Bone Marrow Transplant,2010,45(6):1095-1101.
［14］ 平措卓嘎，左旭盈，王剑利，等.化疗序贯自体造血干细胞移植治疗淋巴瘤的疗效评价及影响因素分析 ［J］.现代肿瘤医学,2022,30(03):509-513. PINGCUO ZG,ZUO XY,WANG JL,et al.Efficacy evaluation and influencing factors of autologous hematopoietic stem cell trans-plantation following chemotherapy in the treatment of lymphoma［J］.Modern Oncology,2022,30(03):509-513.
［15］ 孙艳，郭莉，胡欣，等.大剂量化疗联合自体造血干细胞移植治疗68例淋巴瘤临床疗效分析 ［J］.中华肿瘤防治杂志,2019,26(13):963-968. SUN Y,GUO L,HU X,et al.Clinical analysis of high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation for treatment of lymphoma［J］.Chinese Journal of Cancer Prevention and Treatment,2019,26(13):963-968.
［16］ 冯一梅，张曦.地西他滨在造血干细胞移植中的应用 ［J］.临床血液学杂志,2022,35(01):71-76. FENG YM,ZHANG X.Applications of decitabine in hematopoietic stem cell transplantation［J］.Journal of Clinical Hematology,2022,35(01):71-76.
［17］ 王浩田，董妍，高晓彤，等.ALL儿童方案序贯造血干细胞移植治疗T淋巴母细胞淋巴瘤疗效及预后因素分析 ［J］.中华血液学杂志,2020,41(05):387-393. WANG HT,DONG Y,GAO XT,et al.Analysis of efficacy and prognostic factors of sequential hematopoietic stem cell transplantation for T-lymphoblastic lymphoma by ALL pediatric protocol［J］.Chinese Journal of Hematology,2020,41(05):387-393.
［18］ CANDONI A,LAZZAROTTO D,FERRARA F,et al.Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma.A CAMPUS ALL study ［J］.Am J Hematol,2020,95(12):1466-1472.
［19］ 邹德慧，范磊.造血干细胞移植治疗淋巴瘤中国专家共识(2018版) ［J］.中华肿瘤杂志,2018,40(12):927-934. ZHOU DH,FAN L.The Chinese expert consensus on hematopoietic stem cell transplantation for malignant lymphoma (2018) ［J］.Chinese Journal of Oncology,2018,40(12):927-934.

Memo

Memo:
National Natural Science Foundation of China(No.82070210);国家自然科学基金面上项目（编号：82070210）;河南省医学科技攻关重大项目（编号：SBGJ202001008）
Last Update: 1900-01-01